Profile data is unavailable for this security.
About the company
Novozymes A/S is a Denmark-based biotechnology company engaged in the production and sale of industrial enzymes, microorganisms and biopharmaceutical ingredients. The Company operates in four geographical regions: Europe, Middle East & Africa (including Denmark), North America, Asia Pacific and Latin America. It develops and distributes solutions within the market areas agriculture, bioenergy, food & beverages, household care, leather, pharmaceuticals, forest products, textile and wastewater solutions. Novozymes operates through a range of partnerships with companies, such as Adisseo, Beta Renewables, DONG Energy and Monsanto, and is a parent company of Novozymes Belgium BVBA, Novozymes BioAg Limited, Novozymes Canada Limited, Albumedix A/S and Organobalance GmbH, among others.
- Revenue in DKK (TTM)14.30bn
- Net income in DKK3.09bn
- Incorporated2000
- Employees6.18k
- LocationNovozymes A/SKrogshoejvej 36BAGSVAERD 2880DenmarkDNK
- Phone+45 44460000
- Fax+45 44469999
- Websitehttps://www.novozymes.com/
More ▼
Mergers & acquisitions
| Acquired company | NZYM B:CPH since announced | Transaction value |
|---|---|---|
| Microbiome Labs Physicians Exclusive LLC | 1.84% | 250.00m |
| Precisionbiotics Ltd | -7.75% | 90.00m |
Data delayed at least 15 minutes, as of Jan 15 2021 15:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lanxess AG | 44.56bn | 6.68bn | 41.54bn | 14.35k | 6.15 | 1.67 | 3.71 | 0.9323 | 10.39 | 9.73 | 68.96 | 38.25 | 0.6774 | 3.51 | 7.19 | 418,764.00 | 10.00 | 2.14 | 11.73 | 2.89 | 25.11 | 24.42 | 14.76 | 2.64 | 2.35 | 7.45 | 0.4725 | 42.88 | -0.3224 | -3.21 | 34.21 | 40.25 | -3.72 | 13.70 |
| Uralkaliy PAO | 14.45bn | 1.04bn | 42.65bn | 20.38k | 12.25 | 1.28 | 15.95 | 2.95 | 9.72 | 9.72 | 135.75 | 93.34 | 0.3059 | 3.68 | 5.62 | 8,459,572.00 | 2.19 | 8.38 | 2.68 | 11.54 | 71.46 | 76.18 | 7.17 | 26.41 | 1.44 | 1.73 | 0.7525 | 0.00 | 3.82 | 5.59 | 980.62 | -- | 11.78 | -- |
| Clariant AG | 28.44bn | 1.02bn | 44.34bn | 17.01k | 43.09 | 2.58 | 13.59 | 1.56 | 0.4485 | 0.5941 | 12.47 | 7.48 | 0.5257 | 4.09 | 6.44 | 238,924.70 | 2.22 | 2.32 | 2.98 | 3.35 | 31.91 | 30.76 | 4.23 | 3.45 | 1.11 | 3.66 | 0.4718 | 191.31 | -0.1135 | -6.38 | -129.08 | -- | -2.20 | 49.63 |
| Johnson Matthey PLC | 123.32bn | 861.87m | 44.50bn | 13.94k | 51.53 | 1.97 | 19.62 | 0.3609 | 0.5333 | 0.5333 | 76.35 | 13.96 | 1.99 | 7.80 | 6.75 | 1,057,321.00 | 1.39 | 6.57 | 2.48 | 9.66 | 6.08 | 7.77 | 0.6989 | 2.87 | 0.7888 | 4.56 | 0.3808 | 60.09 | 35.66 | 7.70 | -38.26 | -9.87 | 15.87 | -5.03 |
| Imcd NV | 20.11bn | 801.99m | 44.94bn | 3.05k | 51.61 | 6.57 | 33.44 | 2.24 | 2.05 | 2.05 | 51.49 | 16.14 | 1.26 | 5.91 | 5.85 | 903,602.80 | 5.03 | 5.14 | 7.26 | 6.84 | 20.05 | 19.47 | 3.99 | 4.11 | 0.8293 | 6.62 | 0.5076 | 41.42 | 13.05 | 14.64 | 7.94 | 40.24 | 31.07 | 30.78 |
| Arkema SA | 59.16bn | 2.60bn | 55.17bn | 20.50k | 22.10 | 1.41 | 7.31 | 0.9326 | 4.37 | 4.37 | 99.35 | 68.44 | 0.7499 | 5.88 | 6.40 | 401,961.30 | 3.47 | 5.45 | 4.28 | 6.75 | 19.66 | 21.56 | 4.63 | 6.15 | 1.74 | 5.60 | 0.348 | 33.05 | -0.8848 | 7.98 | -27.15 | 24.07 | 6.34 | 3.53 |
| Chr Hansen Holding A/S | 7.39bn | 1.65bn | 74.36bn | 3.60k | 45.17 | 10.73 | 30.30 | 10.06 | 12.49 | 13.29 | 55.94 | 52.57 | 0.3731 | 2.63 | 6.59 | 2,052,683.00 | 8.34 | 11.44 | 12.14 | 14.14 | 59.13 | 56.72 | 22.36 | 21.87 | 0.2129 | 18.54 | 0.6547 | 59.99 | 3.48 | 2.47 | 1.05 | 7.34 | 11.00 | -- |
| Yara International ASA | 71.13bn | 3.96bn | 74.63bn | 16.03k | 18.91 | 1.49 | 7.75 | 1.05 | 20.46 | 20.46 | 366.62 | 260.19 | 0.713 | 3.69 | 7.48 | 6,167,240.00 | 3.95 | 3.98 | 4.89 | 5.00 | 30.55 | 25.78 | 5.54 | 4.86 | 1.46 | 4.11 | 0.3286 | 108.71 | -0.5415 | -3.13 | 276.73 | -13.11 | -0.8641 | 12.77 |
| Brenntag AG | 89.50bn | 3.46bn | 76.89bn | 17.11k | 22.22 | 2.96 | 13.47 | 0.8592 | 3.01 | 3.01 | 77.96 | 22.58 | 1.41 | 8.12 | 6.71 | 687,771.60 | 5.49 | 5.52 | 7.39 | 7.56 | 22.88 | 21.50 | 3.90 | 3.49 | 1.37 | 10.89 | 0.4093 | 40.28 | 2.17 | 5.06 | 1.26 | 6.58 | 14.65 | 6.79 |
| Novozymes A/S | 14.30bn | 3.09bn | 80.69bn | 6.18k | 31.89 | 9.02 | 18.98 | 5.64 | 10.94 | 10.94 | 50.58 | 38.69 | 0.7099 | 2.36 | 5.04 | 2,451,054.00 | 15.36 | 16.37 | 20.18 | 21.18 | 56.09 | 57.48 | 21.64 | 21.52 | 0.9465 | -- | 0.3355 | 42.19 | -0.1112 | 2.90 | -2.23 | 4.54 | 6.64 | 11.84 |
| Umicore SA | 147.82bn | 1.71bn | 83.22bn | 13.74k | 47.65 | 4.19 | 18.86 | 0.563 | 0.9527 | 0.9527 | 82.17 | 10.85 | 2.83 | 8.15 | 15.25 | 1,406,503.00 | 3.43 | 4.88 | 5.51 | 8.12 | 5.33 | 7.36 | 1.21 | 1.91 | 0.8759 | 5.52 | 0.4859 | 42.87 | 27.47 | 16.56 | -9.21 | 13.01 | 24.87 | -6.89 |
| OMV AG | 131.43bn | -1.99bn | 89.64bn | 19.23k | -- | 0.9767 | 3.68 | 0.682 | -0.8164 | -0.8164 | 53.59 | 37.70 | 0.4342 | 6.94 | 7.16 | 890,299.80 | -0.0246 | 2.09 | -0.0358 | 3.10 | 32.87 | 24.83 | -0.0566 | 3.28 | 1.46 | 47.32 | 0.3824 | 114.83 | 2.32 | -8.16 | 16.69 | 43.27 | -10.86 | 6.96 |
| Evonik Industries AG | 91.28bn | 4.55bn | 93.42bn | 32.82k | 20.57 | 1.51 | 8.60 | 1.02 | 1.31 | 1.19 | 26.24 | 17.80 | 0.5619 | 4.37 | 7.90 | 378,465.90 | 2.88 | 4.17 | 3.44 | 5.05 | 27.82 | 31.01 | 5.12 | 5.96 | 1.14 | 9.98 | 0.3558 | 68.57 | -1.20 | 0.294 | 9.77 | 5.47 | -4.28 | 2.83 |
Data as of Jan 15 2021. Currency figures normalised to Novozymes A/S's reporting currency: Danish Krone DKK
21.79%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Norges Bank Investment Managementas of 31 Dec 2019 | 14.17m | 6.13% |
| Baillie Gifford & Co.as of 08 Jan 2021 | 6.52m | 2.82% |
| MFS International (UK) Ltd.as of 31 Oct 2020 | 6.42m | 2.78% |
| The Vanguard Group, Inc.as of 30 Nov 2020 | 5.83m | 2.52% |
| Canada Pension Plan Investment Boardas of 31 Mar 2020 | 3.39m | 1.47% |
| BlackRock Fund Advisorsas of 07 Jan 2021 | 3.24m | 1.40% |
| Harding Loevner LPas of 30 Nov 2020 | 2.94m | 1.27% |
| Walter Scott & Partners Ltd.as of 30 Nov 2020 | 2.79m | 1.21% |
| Impax Asset Management Ltd.as of 30 Nov 2020 | 2.73m | 1.18% |
| NNIP Advisors BVas of 31 Mar 2020 | 2.35m | 1.02% |
More ▼
Data from 31 Dec 2019 - 30 Nov 2020Source: FactSet Research Systems Inc.
